Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling

Chesnut, Charles H.; McClung, Michael R.; Ensrud, Kristine E.; Bell, Norman H.; Genant, Harry K.; Harris, Steven T.; Singer, Frederick R.; Stock, John L.; Yood, Robert A.; Delmas, Pierre D.; Kher, Uma; Pryor-Tillotson, S.; Santora, Arthur C.

doi:10.1016/s0002-9343(99)80134-x

Cited by 339 publications

(185 citation statements)

References 29 publications

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…77, [93][94][95][96][97][98][99][100][101][102][103][104][105][106][107][108][109][110] In these studies, patients in both the intervention and control groups received calcium and/or vitamin D in comparable doses. Studies in which a bisphosphonate was compared with another active intervention are discussed later (page 36).…”

Section: Bisphosphonatesmentioning

confidence: 99%

“…99 In a further eight studies, vertebral fracture was only included as secondary outcome measure, 94,96,97,101,103,104,107,110 while in a study that included vertebral fracture as an outcome measure, no differentiation between primary and secondary outcome measures was apparent. 95 In two trials, non-vertebral fracture was a primary outcome measure.…”

Section: Bisphosphonatesmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Kanis

Brazier

Stevenson

et al. 2002

Health Technol Assess

207

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.Paying by official purchase order You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care) rather than settings of care. Therefore the panel structure has been redefined and replaced by three new panels: Pharmaceuticals; Therapeutic Procedures (including devices and operations); and Diagnostic Technologies and Screening.The HTA Programme continues to commission both primary and secondary research. The HTA Commissioning Board, supported by the National Coordinating Centre for Health Technology Assessment (NCCHTA), will consider...

show abstract

Section: Bisphosphonatesmentioning

confidence: 99%

Section: Bisphosphonatesmentioning

confidence: 99%

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Kanis

Brazier

Stevenson

et al. 2002

Health Technol Assess

207

View full text Add to dashboard Cite

show abstract

“…Treatment with 10 mg daily increased BMD by 8.6% in the lumbar spine and 6.5% in the femoral neck after 2 years, and indices of bone turnover were reduced (7). The responses to smaller doses were less marked, and higher doses produced no greater effects (7,31).…”

Section: Alendronatementioning

confidence: 97%

“…Serum calcium values decreased modestly with bisphosphonate therapy due to the acute suppression of bone resorption (7). The nadir of this effect occurred within the first month of therapy and was associated with an appropriate elevation of serum parathyroid hormone levels.…”

Section: Alterations In Mineral Metabolismmentioning

confidence: 98%

See 1 more Smart Citation

Bisphosphonates

McClung

2006

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Osteoporosis is the result of bone loss due to an imbalance in bone turnover such that bone resorption exceeds bone formation. Bisphosphonates are potent inhibitors of osteoclast activity that reduce bone turnover and re-establish the balance between bone resorption and formation. In clinical studies, several bisphosphonates prevent bone loss, preserve bone structure, improve bone strength and, in patients with osteoporosis, substantially reduce fracture risk. They are effective in multiple clinical settings including postmenopausal osteoporosis, low bone mass in men and drug-induced bone loss. Intermittent oral dosing and intravenous administration are more convenient than the original daily dosing regimen. These drugs are generally well tolerated and have an excellent safety profile in that serious side effects are uncommon. Potent bisphosphonates are generally the preferred treatment option for most patients with or at risk for osteoporosis. RESUMO Bisfosfonatos.Osteoporose é o resultado da perda óssea devida a um imbalanço no turnover ósseo, onde a reabsorção óssea excede sua formação. Os bisfosfonatos são inibidores potentes da atividade osteoclástica, que reduzem o turnover ósseo e restabelecem o balanço entre a reabsorção e a formação óssea. Em estudos clínicos, vários bisfosfonatos previnem a perda óssea, preservam sua estrutura, melhoram sua força e substancialmente reduzem o risco de fraturas em pacientes com osteoporose. Eles são efetivos em várias situações clínicas, incluindo a osteoporose pós-menopáusica, a reduzida massa óssea em homens e perda óssea induzida por drogas. Doses orais intermitentes e administração intravenosa são mais convenientes do que o esquema original de doses diárias. Essas drogas são geralmente bem toleradas e têm um excelente perfil de segurança, no qual efeitos colaterais sérios são incomuns. Os bisfosfonatos potentes são geralmente a opção terapêutica preferida para a maioria dos pacientes com ou em risco de osteoporose. O STEOPOROSIS IS A DISORDER of skeletal fragility due a combination of low bone mass, deteriorated bone architecture and perhaps alterations in other aspects of bone quality (1). Osteoporosis is usually the result of bone loss that occurs after menopause in women and in older men and women. This bone loss is a consequence of increased and unbalanced bone review article Bisphosphonates

show abstract

Alendronate Treatment to Prevent Osteoporotic Fractures

Ragsdale

Barringer²,

Anastasio³

1998

Archives of Family Medicine

View full text Add to dashboard Cite

Alendronate sodium, an aminobisphosphonate, has been approved by the Food and Drug Administration for the prevention and treatment of osteoporosis in postmenopausal women, thus providing an effective alternative to estrogen replacement therapy in women who cannot or will not take estrogen. Large, randomized, controlled trials have demonstrated approximately a 50% reduction in vertebral, hip, and wrist fractures. Efficacy and safety beyond 3 years has not been determined. To avoid esophagitis and maximize absorption, alendronate should be taken with 180 to 240 mL of water on arising for the day, allowing at least 30 minutes before the first food, beverage, or oral medication of the day is ingested.

show abstract

Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling

Cited by 339 publications

References 29 publications

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Bisphosphonates

Alendronate Treatment to Prevent Osteoporotic Fractures

Contact Info

Product

Resources

About